glp 1 therapy for diabetes GLP-1 receptor agonists are transforming care by improving blood sugar control, supporting weight loss, and reducing cardiovascular risk when used appropriately. Evidence-based selection, correct dosing, and patient counseling are UC Davis Health examines systemic
Description
Study design of retrospective clinical study and patient selection The single-center retrospective clinical study was conducted at Division of nephrology, Kurume University Hospital
[DOI] [PubMed] [Google Scholar] 88.Friedrichsen BN, Neubauer N, Lee YC, Gram VK, Blume N, et al
A double blinded placebo controlled study using daily Orfoglipron (45 mg) in obese patients, found an average of 12.4% decrease in body weight over placebo after 36 weeks
Drop 100-plus pounds and sagging skin is likely
Pregnancy or breastfeeding, since it is unclear if these drugs are safe for those groups
